references/iso-regulatory-requirements.md
ISO Regulatory Requirements for Medical Devices
Key ISO standards applicable to medical device development, quality management, and regulatory compliance.
Table of Contents
- ISO 13485 Quality Management
- ISO 14971 Risk Management
- ISO 10993 Biocompatibility
- IEC 62304 Software Lifecycle
- IEC 62366 Usability Engineering
- ISO 11607 Packaging Validation
- Sterilization Standards
- Standards Cross-Reference
ISO 13485 Quality Management
ISO 13485:2016 Overview
| Aspect | Requirement | |--------|-------------| | Scope | QMS for design, development, production, installation, and servicing | | Certification | Third-party certification required for most markets | | Regulatory Status | Harmonized under EU MDR; recognized by FDA QSIT | | Validity | 3-year certification cycle with annual surveillance |
Key Clause Requirements
| Clause | Title | Regulatory Focus | |--------|-------|------------------| | 4.1 | General Requirements | Process-based QMS, outsourcing control | | 4.2 | Documentation | Quality Manual, procedures, records | | 5.1-5.6 | Management Responsibility | Policy, planning, review | | 6.1-6.4 | Resource Management | Competence, infrastructure, environment | | 7.1 | Planning | Risk management integration | | 7.2 | Customer-Related | Requirements determination and review | | 7.3 | Design and Development | Design controls (critical for FDA) | | 7.4 | Purchasing | Supplier controls | | 7.5 | Production | Process validation, identification, traceability | | 7.6 | Monitoring Equipment | Calibration | | 8.2 | Monitoring | Feedback, complaints, audits | | 8.3 | Nonconforming Product | Control and disposition | | 8.5 | Improvement | CAPA |
Design Control Requirements (Clause 7.3)
| Stage | Clause | Deliverables | |-------|--------|--------------| | Planning | 7.3.2 | Design plan, stages, responsibilities | | Inputs | 7.3.3 | Requirements specification | | Outputs | 7.3.4 | Design specifications, acceptance criteria | | Review | 7.3.5 | Design review records | | Verification | 7.3.6 | Verification testing reports | | Validation | 7.3.7 | Validation protocols and reports | | Transfer | 7.3.8 | Transfer verification records | | Changes | 7.3.9 | Change control records |
Regulatory Mapping
| Regulation | ISO 13485 Recognition | |------------|----------------------| | EU MDR 2017/745 | Harmonized standard (presumption of conformity) | | FDA 21 CFR 820 | Substantially equivalent; QSIT alignment | | Health Canada | MDSAP or direct recognition | | PMDA Japan | Recognized with MHLW certification | | TGA Australia | Accepted as conformity evidence | | ANVISA Brazil | Required for GMP compliance |
ISO 14971 Risk Management
ISO 14971:2019 Overview
| Aspect | Requirement | |--------|-------------| | Scope | Risk management throughout medical device lifecycle | | Regulatory Status | Harmonized under EU MDR; referenced by FDA | | Key Change (2019) | Enhanced benefit-risk analysis emphasis | | Documentation | Risk management file required |
Risk Management Process
| Stage | Activities | Outputs | |-------|------------|---------| | Planning | Define scope, responsibilities, criteria | Risk management plan | | Risk Analysis | Identify hazards, estimate risk | Hazard analysis, risk estimation | | Risk Evaluation | Compare against acceptability criteria | Risk evaluation records | | Risk Control | Select and implement controls | Risk control measures | | Residual Risk | Evaluate remaining risk | Residual risk evaluation | | Risk-Benefit | Assess overall benefit-risk | Benefit-risk analysis | | Review | Periodic risk management review | Risk management report |
Risk Analysis Methods
| Method | Application | Standard Reference | |--------|-------------|-------------------| | FMEA | Component/process failure modes | IEC 60812 | | FTA | System-level failure analysis | IEC 61025 | | HAZOP | Process hazard identification | IEC 61882 | | PHA | Preliminary hazard assessment | - |
Risk Acceptability Matrix
| Severity | Probability | Risk Level | Action | |----------|-------------|------------|--------| | Catastrophic | Frequent | Unacceptable | Design change required | | Critical | Probable | ALARP | Risk reduction required | | Serious | Occasional | ALARP | Risk reduction if practicable | | Minor | Remote | Acceptable | Monitor | | Negligible | Improbable | Acceptable | Document |
Post-Production Risk Management
| Activity | Frequency | Sources | |----------|-----------|---------| | Complaint Analysis | Continuous | Customer complaints | | Vigilance Review | Continuous | Adverse event reports | | Literature Review | Annual | Scientific publications | | Standards Review | Annual | Updated standards | | Risk File Update | As needed | New information |
ISO 10993 Biocompatibility
ISO 10993-1:2018 Biological Evaluation Framework
| Contact Type | Duration | Required Tests | |--------------|----------|----------------| | Surface - Skin | Limited (<24h) | Cytotoxicity, sensitization, irritation | | Surface - Mucosal | Prolonged (24h-30d) | + Acute systemic toxicity | | Surface - Breached | Permanent (>30d) | + Subchronic toxicity, genotoxicity | | External Communicating | Limited | Cytotoxicity, sensitization, irritation, hemolysis | | External Communicating | Prolonged | + Subchronic toxicity, implantation | | External Communicating | Permanent | + Chronic toxicity, carcinogenicity | | Implant | Limited | Full biological evaluation | | Implant | Prolonged/Permanent | Comprehensive testing including implantation |
Key Test Standards
| Standard | Test | |----------|------| | ISO 10993-3 | Genotoxicity, carcinogenicity, reproductive toxicity | | ISO 10993-4 | Hemocompatibility | | ISO 10993-5 | Cytotoxicity (in vitro) | | ISO 10993-6 | Local effects after implantation | | ISO 10993-10 | Irritation and skin sensitization | | ISO 10993-11 | Systemic toxicity | | ISO 10993-12 | Sample preparation and reference materials | | ISO 10993-18 | Chemical characterization |
Biocompatibility Evaluation Workflow
- Define device contact nature and duration
- Identify materials in contact with body
- Perform chemical characterization (ISO 10993-18)
- Conduct gap analysis against required endpoints
- Plan and execute required testing
- Document biological evaluation report
- Update for material or design changes
- Validation: All endpoints addressed; testing per GLP; BE report complete
IEC 62304 Software Lifecycle
IEC 62304:2006/AMD1:2015 Overview
| Aspect | Requirement | |--------|-------------| | Scope | Medical device software development lifecycle | | Regulatory Status | Harmonized under EU MDR; FDA guidance reference | | Key Concept | Safety classification drives rigor | | Documentation | Software development plan, architecture, testing |
Software Safety Classification
| Class | Definition | Documentation Rigor | |-------|------------|---------------------| | A | No injury or damage possible | Basic | | B | Non-serious injury possible | Moderate | | C | Death or serious injury possible | High |
Required Processes by Class
| Process | Class A | Class B | Class C | |---------|---------|---------|---------| | Software Development Planning | Required | Required | Required | | Software Requirements Analysis | Required | Required | Required | | Software Architecture Design | - | Required | Required | | Software Detailed Design | - | - | Required | | Software Unit Implementation | Required | Required | Required | | Software Unit Verification | - | Required | Required | | Software Integration Testing | Required | Required | Required | | Software System Testing | Required | Required | Required | | Software Release | Required | Required | Required | | Software Maintenance | Required | Required | Required | | Software Risk Management | Required | Required | Required | | Software Configuration Management | Required | Required | Required | | Software Problem Resolution | Required | Required | Required |
Documentation Requirements
| Document | Class A | Class B | Class C | |----------|---------|---------|---------| | Software Development Plan | ✓ | ✓ | ✓ | | Software Requirements Specification | ✓ | ✓ | ✓ | | Software Architecture Document | - | ✓ | ✓ | | Software Detailed Design | - | - | ✓ | | Software Unit Test Records | - | ✓ | ✓ | | Integration Test Records | ✓ | ✓ | ✓ | | System Test Records | ✓ | ✓ | ✓ | | Traceability Matrix | - | ✓ | ✓ |
IEC 62366 Usability Engineering
IEC 62366-1:2015 Overview
| Aspect | Requirement | |--------|-------------| | Scope | Usability engineering process for medical devices | | Regulatory Status | Harmonized under EU MDR; FDA HFE guidance | | Key Concept | Use-related risk identification and mitigation | | Documentation | Usability engineering file |
Usability Engineering Process
| Stage | Activities | Outputs | |-------|------------|---------| | Use Specification | Define users, use environments, user interface | Use specification document | | User Interface Design | Design UI with task analysis input | UI specifications | | Hazard Analysis | Identify use-related hazards | Use-related risk analysis | | Formative Evaluation | Iterative design testing | Formative evaluation reports | | Summative Evaluation | Final design validation | Summative evaluation report | | Documentation | Compile usability engineering file | UEF |
Usability Testing Requirements
| Test Type | Purpose | Participants | |-----------|---------|--------------| | Formative | Identify usability issues during design | Representative users (5-8 per iteration) | | Summative | Validate final design | Representative users (15+ per user group) | | Simulated Use | Test under realistic conditions | Trained users in simulated environment | | Actual Use | Validate in clinical setting | Actual users in actual environment |
Usability Engineering File Contents
| Section | Content | |---------|---------| | Use Specification | User profiles, use environments, user interface | | Use-Related Risk Analysis | Hazard identification, risk evaluation | | UI Design Specifications | Design requirements, rationale | | Formative Evaluation | Test protocols, results, design changes | | Summative Evaluation | Validation protocol, results, conclusions | | Residual Risk | Remaining use-related risks |
ISO 11607 Packaging Validation
ISO 11607-1:2019 and ISO 11607-2:2019
| Part | Scope | |------|-------| | Part 1 | Requirements for materials, sterile barrier systems, packaging systems | | Part 2 | Validation requirements for forming, sealing, and assembly processes |
Packaging Validation Stages
| Stage | Activities | Documentation | |-------|------------|---------------| | IQ | Equipment installation verification | Installation records | | OQ | Process parameter verification | OQ protocol and report | | PQ | Performance under production conditions | PQ protocol and report |
Required Testing
| Test | Standard | Purpose | |------|----------|---------| | Seal Strength | ASTM F88 | Peel strength measurement | | Seal Integrity | ASTM F2095 | Bubble leak test | | Visual Inspection | ISO 11607-1 | Defect identification | | Package Integrity | ASTM D4169 | Distribution simulation | | Accelerated Aging | ASTM F1980 | Shelf life validation | | Real-Time Aging | - | Stability confirmation |
Shelf Life Validation
| Method | Approach | Considerations | |--------|----------|----------------| | Accelerated Aging | Q10 = 2 (typically) | Per ASTM F1980 | | Real-Time Aging | Concurrent with accelerated | Required for final claim | | Worst-Case Testing | Post-aging integrity testing | Distribution + storage conditions |
Sterilization Standards
Common Sterilization Methods
| Method | Standard | Applications | |--------|----------|--------------| | EO (Ethylene Oxide) | ISO 11135:2014 | Heat/moisture sensitive | | Steam | ISO 17665-1:2006 | Heat/moisture tolerant | | Radiation | ISO 11137:2017 | Heat sensitive, high volume | | Dry Heat | ISO 20857:2010 | Moisture sensitive | | Aseptic Processing | ISO 13408 | Prefilled syringes |
Sterilization Validation Requirements
| Phase | Activities | Documentation | |-------|------------|---------------| | IQ | Equipment installation | Installation records | | OQ | Process parameter qualification | OQ protocol and report | | PQ | Microbiological performance | Bioburden, SAL demonstration | | Routine Control | Process monitoring | Batch records, BI results |
Sterility Assurance Level (SAL)
| SAL | Probability of Non-Sterile | Application | |-----|----------------------------|-------------| | 10⁻⁶ | 1 in 1 million | Most medical devices | | 10⁻³ | 1 in 1,000 | Aseptically processed |
Standards Cross-Reference
Regulatory Alignment
| Standard | EU MDR | FDA | Health Canada | TGA | |----------|--------|-----|---------------|-----| | ISO 13485 | Harmonized | Recognized | Required | Accepted | | ISO 14971 | Harmonized | Referenced | Required | Accepted | | ISO 10993 | Harmonized | Referenced | Required | Accepted | | IEC 62304 | Harmonized | Referenced | Required | Accepted | | IEC 62366 | Harmonized | Referenced | Required | Accepted |
Version Requirements
| Standard | Current Version | Transition Deadline | |----------|-----------------|---------------------| | ISO 13485 | 2016 | Active | | ISO 14971 | 2019 | Active | | ISO 10993-1 | 2018 | Active | | IEC 62304 | 2006/Amd1:2015 | Active | | IEC 62366-1 | 2015/Amd1:2020 | Active |
Certification Bodies
| Region | Certification Body Type | |--------|------------------------| | EU | Notified Bodies (per MDR) | | USA | FDA-recognized accreditation bodies | | MDSAP | Authorized auditing organizations | | Global | ISO certification bodies (IATF, DNV, BSI, TÜV) |